Company

Sinew Pharma, Inc.

Headquarters: Taipei City, Taiwan

Employees: 33

CEO: Dr. Kaimin Chu M.D., Ph.D.

TWSE: 6634 -1.52%

Market Cap

TW$5.59 Billion

TWD as of July 1, 2024

US$171.8 Million

Market Cap History

Sinew Pharma, Inc. market capitalization over time

Evolution of Sinew Pharma, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Sinew Pharma, Inc.

Detailed Description

Sinew Pharma Inc., a biopharmaceutical company, focuses on the development and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company's products include SNP-610 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan; and SNP-630, a pre-clinical drug for treating patients with non-alcoholic steatohepatitis. It is also developing SNP-810 for use in analgesic and antipyretic indications; and SNP-830 and SNP-840, which are used as hepatotoxicity-free analgesic medicines in the United States. The company was founded in 2014 and is based in Taipei City, Taiwan.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Sinew Pharma, Inc. has the following listings and related stock indices.


Stock: TWSE: 6634 wb_incandescent

Details

Headquarters:

No. 3, Yuanqu Street

14 Floor-5 Nangang District

Taipei City, 115

Taiwan

Phone: 886 2 2655 7269

Fax: 886 2 2655 7179